CADL · Candel Therapeutics Inc
United States · RS rating 58 · As of 2026-11-03
| Price | 8.82 USD |
|---|---|
| 1-day change | +8.6% |
| RS rating (overall / 1M / 3M / 12M) | 58 / 29 / 37 / 89 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 28 / 29 / 16 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -157.1% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +35.9% |
| Market cap (USD) | $515.7M |